Cisplatin, also known as cisplatinum
or cis-diamminedichloroplatinum(II), is a
chemotherapy drug used to treat various types of cancer including sarcomas,
lymphomas, germ cell tumors and some carcinomas (e.g. small cell lung cancer,
ovarian cancer).
This molecule was first
created in mid-19th century, being its discoverer Michel Peyronie.
Cisplatin belongs to a class of platinum-containing anti-cancer drugs and it was the first
medicine developed in this class.
The
molecule’s platinum complex reacts in vivo, binding with DNA forming intra-strand
crosslinks which causes a conformational change in DNA affecting its
replication. Cisplatin cytotoxicity is increased during S-phase and causes cell
cycle to cease in the G2-phase, ultimately triggering apoptosis,
i.e. programmed cell death.
Other mechanisms of cisplatin’s cytotoxicity include
decreased ATPase activity, mitochondrial damage and altered cellular transport
mechanisms.
Cisplatin-induced
cellular destruction can result in tumor lysis syndrome (TLS) which includes
hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, which means,
respectively, high concentrations of K+, phosphate and uric acid in the
blood, and low concentration of serum calcium, also in the blood.